These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 19813061)

  • 21. Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas.
    Kim JC; Choi JS; Roh SA; Cho DH; Kim TW; Kim YS
    Ann Surg Oncol; 2010 Jul; 17(7):1767-76. PubMed ID: 20077021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exclusive KRAS mutation in microsatellite-unstable human colorectal carcinomas with sequence alterations in the DNA mismatch repair gene, MLH1.
    Zhao Y; Miyashita K; Ando T; Kakeji Y; Yamanaka T; Taguchi K; Ushijima T; Oda S; Maehara Y
    Gene; 2008 Nov; 423(2):188-93. PubMed ID: 18692554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
    Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
    Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic Value of BRAF and KRAS Mutation in Relation to Colorectal Cancer Survival in Iranian Patients: Correlated to Microsatellite Instability.
    Nazemalhosseini-Mojarad E; Kishani Farahani R; Mehrizi M; Baghaei K; Yaghoob Taleghani M; Golmohammadi M; Peyravian N; Ashtari S; Pourhoseingholi MA; Asadzadeh Aghdaei H; Zali MR
    J Gastrointest Cancer; 2020 Mar; 51(1):53-62. PubMed ID: 30635874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
    Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA
    Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution.
    Sylvester BE; Huo D; Khramtsov A; Zhang J; Smalling RV; Olugbile S; Polite BN; Olopade OI
    Clin Cancer Res; 2012 Jan; 18(2):350-9. PubMed ID: 22114137
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential expression of CD133 based on microsatellite instability status in human colorectal cancer.
    Park JJ; Kwon JH; Oh SH; Choi J; Moon CM; Ahn JB; Hong SP; Cheon JH; Kim TI; Kim H; Kim WH
    Mol Carcinog; 2014 Feb; 53 Suppl 1():E1-10. PubMed ID: 23065858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer.
    Sanchez JA; Krumroy L; Plummer S; Aung P; Merkulova A; Skacel M; DeJulius KL; Manilich E; Church JM; Casey G; Kalady MF
    Br J Surg; 2009 Oct; 96(10):1196-204. PubMed ID: 19787768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. KRAS and BRAF mutations and MSI status in precursor lesions of colorectal cancer detected by colonoscopy.
    Yamane LS; Scapulatempo-Neto C; Alvarenga L; Oliveira CZ; Berardinelli GN; Almodova E; Cunha TR; Fava G; Colaiacovo W; Melani A; Fregnani JH; Reis RM; Guimarães DP
    Oncol Rep; 2014 Oct; 32(4):1419-26. PubMed ID: 25050586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathologic and molecular characteristics of synchronous colorectal cancers: heterogeneity of clinical outcome depending on microsatellite instability status of individual tumors.
    Bae JM; Cho NY; Kim TY; Kang GH
    Dis Colon Rectum; 2012 Feb; 55(2):181-90. PubMed ID: 22228162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers.
    Ogino S; Nosho K; Irahara N; Shima K; Baba Y; Kirkner GJ; Meyerhardt JA; Fuchs CS
    J Clin Oncol; 2009 Sep; 27(27):4591-8. PubMed ID: 19704056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
    BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High MACC1 expression in combination with mutated KRAS G13 indicates poor survival of colorectal cancer patients.
    Ilm K; Kemmner W; Osterland M; Burock S; Koch G; Herrmann P; Schlag PM; Stein U
    Mol Cancer; 2015 Feb; 14():38. PubMed ID: 25742883
    [TBL] [Abstract][Full Text] [Related]  

  • 34. K-Ras and MSI: potential markers of both patient prognosis and treatment efficacy.
    Turaga K; Shibata D
    Ann Surg Oncol; 2010 Feb; 17(2):354-5. PubMed ID: 19936842
    [No Abstract]   [Full Text] [Related]  

  • 35. Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer.
    Birgisson H; Edlund K; Wallin U; Påhlman L; Kultima HG; Mayrhofer M; Micke P; Isaksson A; Botling J; Glimelius B; Sundström M
    BMC Cancer; 2015 Mar; 15():125. PubMed ID: 25884297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of HPV with genetic and epigenetic alterations in colorectal adenocarcinoma from Indian population.
    Laskar RS; Talukdar FR; Choudhury JH; Singh SA; Kundu S; Dhar B; Mondal R; Ghosh SK
    Tumour Biol; 2015 Jun; 36(6):4661-70. PubMed ID: 25647260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence for possible non-canonical pathway(s) driven early-onset colorectal cancer in India.
    Raman R; Kotapalli V; Adduri R; Gowrishankar S; Bashyam L; Chaudhary A; Vamsy M; Patnaik S; Srinivasulu M; Sastry R; Rao S; Vasala A; Kalidindi N; Pollack J; Murthy S; Bashyam M
    Mol Carcinog; 2014 Feb; 53 Suppl 1(0 1):E181-6. PubMed ID: 23168910
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
    Zhang X; Wang Y; Gao N; Wang J
    Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.
    Zlobec I; Bihl MP; Schwarb H; Terracciano L; Lugli A
    Int J Cancer; 2010 Jul; 127(2):367-80. PubMed ID: 19908233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer.
    Kure S; Nosho K; Baba Y; Irahara N; Shima K; Ng K; Meyerhardt JA; Giovannucci EL; Fuchs CS; Ogino S
    Cancer Epidemiol Biomarkers Prev; 2009 Oct; 18(10):2765-72. PubMed ID: 19789368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.